05Y:F VIVORYON THERAPEUTICS

EUR 0.53 -0.01 -1.48423
Icon

VIVORYON THERAPEUTICS (05Y:F) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | F
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 0.531

-0.01 (-1.48)%

EUR 0.01B

9.00K

N/A

N/A

Icon

05Y:F

VIVORYON THERAPEUTICS (EUR)
COMMON STOCK | F
EUR 0.53
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 0.01B

N/A

EUR 0.53

VIVORYON THERAPEUTICS (05Y:F) Stock Forecast

N/A

Based on the VIVORYON THERAPEUTICS stock forecast from 0 analysts, the average analyst target price for VIVORYON THERAPEUTICS is not available over the next 12 months. VIVORYON THERAPEUTICS’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of VIVORYON THERAPEUTICS is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, VIVORYON THERAPEUTICS’s stock price was EUR 0.531. VIVORYON THERAPEUTICS’s stock price has changed by -0.93% over the past week, -94.10% over the past month and -95.98% over the last year.

No recent analyst target price found for VIVORYON THERAPEUTICS
No recent average analyst rating found for VIVORYON THERAPEUTICS

Company Overview VIVORYON THERAPEUTICS

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The co...Read More

N/A

N/A

15

December

EUR

Germany

Adjusted Closing Price for VIVORYON THERAPEUTICS (05Y:F)

Loading...

Unadjusted Closing Price for VIVORYON THERAPEUTICS (05Y:F)

Loading...

Share Trading Volume for VIVORYON THERAPEUTICS Shares

Loading...

Compare Performance of VIVORYON THERAPEUTICS Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for 05Y:F

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To VIVORYON THERAPEUTICS (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NOVA:F
Novo Nordisk A/S -1.50 (-1.26%) EUR506.56B 45.40 4.43

ETFs Containing 05Y

Symbol Name 05Y's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About VIVORYON THERAPEUTICS (05Y:F) Stock

Stock Target Advisor's fundamental analysis for VIVORYON THERAPEUTICS's stock is Slightly Bearish.

Unfortunately we do not have enough data on 05Y:F's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on 05Y:F's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on 05Y:F's stock to indicate if its overvalued.

The last closing price of 05Y:F's stock was EUR 0.53.

The most recent market capitalization for 05Y:F is EUR 0.01B.

Unfortunately we do not have enough analyst data on 05Y:F's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains VIVORYON THERAPEUTICS's stock.

As per our most recent records VIVORYON THERAPEUTICS has 15 Employees.

Sorry we do not have any infomation available on VIVORYON THERAPEUTICS's address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...